Precision Treatment of Metachronous Multiple Primary Malignancies Using Patient-Derived Organoids
Author Information
Author(s): Wang Yicheng, Chen Haotian, Zhang Zhijin, He Yanyan, Liu Ji, Zhao Baoshuang, Wang Qinwan, Xu Jiangmei, Mao Shiyu, Zhang Wentao, Yao Xudong, Li Wei
Primary Institution: Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
Hypothesis
Can patient-derived organoids be used to guide personalized treatment for patients with multiple primary malignant neoplasms?
Conclusion
The study successfully established patient-derived organoids from a patient with four primary tumors, which can help in predicting drug sensitivity and guiding personalized treatment.
Supporting Evidence
- The patient had four primary tumors: bladder cancer, lung adenocarcinoma, prostate adenocarcinoma, and clear cell renal cell carcinoma.
- Patient-derived organoids accurately reflected the histopathological features of the original tumors.
- Organoids can be used to predict drug responses and guide personalized treatment strategies.
Takeaway
This study is about a patient who had four different cancers, and scientists created mini-tumors from his cancer cells to find the best treatment for him.
Methodology
The study involved isolating renal cancer tissues from a patient to create organoids, which were then analyzed for histopathological characteristics and drug response.
Limitations
The organoids cannot replicate blood perfusion, mechanical stress, or a fully integrated immune microenvironment, limiting their ability to simulate interactions between multiple primary tumors.
Participant Demographics
A 73-year-old male patient with multiple primary malignant neoplasms.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website